First, HHS is committing up to 4.9 million through the Advanced Research Projects Agency for Health ARPA H to advance ibogaine treatment for PTSD. These awards will support scientific and regulatory manufacturing work necessary to prepare for future US Clinical trials. Mark Cuban Cause plus drug company will develop the regulatory and manufacturing processes needed to produce single model molecule I began hydrochloride in the United States for study for potential PTS treatments. Mark Cuban's company has agreed to cost plus contracts that are transparent. We're going to open source every aspect of this system so that we know that we're getting the … (09:43–10:00)
STATEMENT
Asserts that Mark Cuban's company will develop processes to produce ibogaine hydrochloride in the U.S. for PTSD study.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.